Credits: Canva
As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.
As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."
The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.
The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.
Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.
As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.
A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.
TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."
Credit: University of Utah
A popular kratom drink, often marketed as a natural alternative to pharmaceutical drugs, could become the next major addiction crisis in the United States, addiction specialists are warning.
The substance, sometimes dubbed "gas-station heroin," is already banned in at least eight US states—Alabama, Arkansas, Connecticut, Indiana, Louisiana, Tennessee, Vermont, and Wisconsin. Several other states, including Iowa and Idaho, are considering restrictions or outright bans.
Tennessee looks to make a statewide ban effective from July 1. Earlier this month, Idaho Falls approved a local ban on kratom sales that will also take effect on July 1, the media report said.
While some jurisdictions are targeting synthetic forms of kratom rather than the plant itself, concerns over addiction, overdose risks, and easy accessibility continue to grow.
Last year, US Health and Human Services Secretary Robert F. Kennedy Jr. criticized the widespread availability of kratom products, many of which are sold at gas stations and marketed in child-friendly forms such as gummies.
"It is a sinister, sinister industry," Kennedy said.
Kratom is a plant-based substance derived from the Mitragyna speciosa tree, native to Southeast Asia. Traditionally used in countries such as Thailand and Malaysia for pain relief and increased energy, it has gained popularity in the US as an over-the-counter supplement.
Kratom products are sold in various forms, including powders, capsules, teas, drinks, and gummies.
At lower doses, kratom acts as a stimulant. At higher doses, it can produce sedative and opioid-like effects. While it remains legal in many parts of the US, the Food and Drug Administration (FDA) has classified kratom as a "drug of concern" and has not approved it for any medical use.
Also read: Trying to Quit Tobacco? Yoga Could Improve Your Chances, Suggests Study
Health experts point to a sharp increase in kratom-related hospitalizations as evidence of a growing problem.
According to a University of Virginia study, there were 43 hospitalizations linked solely to kratom in 2015. By 2025, that number had risen to 538.
Researchers noted that the surge coincided with the emergence of highly concentrated synthetic products, including 7-hydroxymitragynine (7-OH), a potent kratom-derived compound.
"It is increasing the prevalence of opioid use disorder," Dr. Andrew Kolodny, director of the Opioid Policy Research Collaborative at Brandeis University, was quoted as saying to The Guardian.
"Being able to buy an opioid at a convenience store is going to make the opioid crisis worse," he added.
Mac Haddow, the association's senior fellow for public policy, denied that kratom itself is inherently addictive or dangerous. He argued that the real issue is 7-OH, which is significantly more potent than traditional kratom powder.
7-hydroxymitragynine (7-OH) is a naturally occurring compound found in kratom, and it is far more potent. While kratom itself contains a mixture of alkaloids, 7-OH is an isolated extract or concentrated form that interacts with the body’s opioid receptors much more strongly.
Read More: Taking Duloxetine? US FDA Warns of Cancer-Causing Impurity in Antidepressant
Dr. Angad Madan, Medical Director of St. Peter's Addiction Recovery Center (SPARC), said many users mistakenly believe kratom is simply a harmless herbal supplement.
"Many patients do not know that it's a substance of addiction or misuse. Many patients just think it's a herbal supplement. I think it's false advertising, and it's resulting in another opioid epidemic that New York doesn't really need," he was quoted as saying to WNYT.
Madan added that kratom-related dependence is becoming increasingly common in treatment settings.
"Kratom, also known as 7-OH or 7-hydroxymitragynine, is the number one new substance addiction that I've seen at SPARC across all levels of care," he said.
Credit: iStock
Hypertension remains one of the leading causes of illness and premature death worldwide. Yet a handful of countries have managed to significantly reduce their impact through effective public health strategies.
South Korea—best known globally for K-pop, K-dramas, and K-beauty—is among just four countries in the world to achieve a hypertension control rate above 50 per cent, joining Canada, Costa Rica, and Iceland.
According to the latest Korea Hypertension Fact Sheet, South Korea's blood pressure control rate has climbed to 62 per cent, making it one of the highest in the world. This means that more than half of people diagnosed with high blood pressure have successfully brought it within a healthy range through treatment.
"The Republic of Korea is one of only four countries in the world that have reached a hypertension control rate above 50 per cent," said World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus in a post on X.
Canada, Costa Rica, and Iceland also have hypertension control rates exceeding 50 per cent.
"South Korea continues to demonstrate high performance in hypertension management at the population level, with steady improvements in awareness, treatment, and control," the fact sheet, published in the journal Clinical Hypertension, noted.
Also read: Heatwaves, Ozone Pollution Driving Heart And Lung Disease Deaths In India: IIT Study
According to the WHO, South Korea's hypertension control rate was only about 5 per cent two decades ago. Since then, the country has achieved a remarkable turnaround, contributing to an estimated 83 per cent reduction in stroke-related deaths.
“It’s the single most important thing to get right in healthcare… but most countries don’t,” Dr Tom Frieden, president of Resolve to Save Lives, an initiative working on global health threats, told The Telegraph. “South Korea is one of the rare successes in the world, on both the treatment and prevention of high blood pressure.”
As per experts, Korea's success is a result of
"Globally, every hour, over 1,000 lives are lost to strokes and heart attacks from high blood pressure, while hypertension control is one of the most cost-effective interventions in public health. This is why I call on world and health leaders to heed the Republic of Korea's experience," Tedros added.
Also read: 16 Million Indians Die Due To Hypertension Every Year: AIIMS Doc
Prof. Hyeon Chang Kim, Professor in the Department of Preventive Medicine at Yonsei University College of Medicine, highlighted three key lessons from South Korea's success that other countries can adopt to improve hypertension control.
1. Make Hypertension Control a Health-System Priority
2. Invest in Data and Monitoring
3. Ensure Long-Term Continuity of Care
The South Korean experience shows that sustained care, regular follow-up, and strong healthcare systems can significantly improve blood pressure control and reduce deaths from heart disease and stroke.
The Lancet estimates that approximately 1.7 billion adults worldwide are living with hypertension. However, fewer than 20 per cent have their blood pressure adequately controlled.
Hypertension can quietly damage the heart, brain, kidneys, and blood vessels for years before symptoms appear. Because it often causes no noticeable signs, many people remain unaware they have the condition.
"Nine out of 10 times, hypertension does not cause symptoms. The only way to detect it is through regular screening," said Dr. Ambuj Roy, Professor of Cardiology at the All India Institute of Medical Sciences (AIIMS), New Delhi.
To help reduce blood pressure and improve heart health, Dr. Roy recommends:
Credit: breckenridgepharma.com
Duloxetine, a widely prescribed antidepressant, has been recalled in the United States after the US Food and Drug Administration (FDA) found potentially cancer-causing impurities above federal safety limits.
According to the Cleveland Clinic, duloxetine is commonly used to treat depression, anxiety, fibromyalgia, and certain chronic pain conditions.
The FDA issued a notice stating the presence of N-nitroso-duloxetine, a nitrosamine impurity detected at levels exceeding the agency's recommended safety threshold. The recall affects nearly 370,000 bottles of prescription-only duloxetine delayed-release capsules USP, 30mg, 1000 Capsule bottles, distributed across the US.
The agency warned that exposure to nitrosamine impurities "may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time."
The agency classified the action as a Class II recall, indicating that use of or exposure to the product may cause temporary or medically reversible adverse health consequences, while the likelihood of serious health effects remains low.
Also read: US FDA Approves First New Sunscreen Ingredient Since the 1990s
Notably, this is the second duloxetine recall linked to the same impurity. In October 2024, more than 7,000 bottles were recalled because of potential nitrosamine contamination.
According to the FDA, people who take medications containing nitrosamines—even daily for up to 70 years—are not expected to face an increased cancer risk if nitrosamine levels remain at or below the recommended limits.
There is currently no direct evidence linking N-nitroso-duloxetine itself to cancer. However, it belongs to a class of compounds known as nitrosamines, some of which are considered probable human carcinogens.
Moreover, health risks associated with nitrosamines generally depend on both the amount and duration of exposure. Higher levels over extended periods are considered more concerning.
The US National Library of Medicine describes N-nitroso-duloxetine as a compound that is "suspected of causing cancer" and notes that it is toxic if swallowed.
At the same time, the California State Board of Pharmacy emphasizes that exposure does not automatically result in cancer. The agency notes that nitrosamines are commonly found in water and foods, including cured and grilled meats, dairy products, and vegetables.
"Everyone is exposed to some level of nitrosamines," the board states. "These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time."
Read More: New Pancreatic Cancer Drug Daxaronrasib May Benefit Patients With Lung And Ovarian Tumors Too
Antidepressants are prescription medications used to treat depression, anxiety disorders, chronic pain, and other conditions by increasing levels of certain brain chemicals involved in mood regulation.
Common classes of antidepressants include:
These medications often take several weeks to achieve their full therapeutic effect. Common side effects may include dry mouth, dizziness, nausea, and weight changes. Emerging research also suggests that side effects can vary significantly depending on the specific medication.
Duloxetine belongs to a class of antidepressants known as SNRIs.
Cleveland Clinic explained that duloxetine is used to treat depression, generalized anxiety disorder, fibromyalgia, and certain types of chronic pain, including nerve, bone, and joint pain.
The medication works by increasing levels of serotonin and norepinephrine in the brain—neurotransmitters that help regulate mood and pain perception.
© 2024 Bennett, Coleman & Company Limited